The gut hormones in appetite regulation

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Suzuki, Keisuke ^a   Jayasena, Channa N ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865068238     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/528401     Document Type: Review

References (132)

1. Field A. E., Coakley E. H., Must A., Spadano J. L., Laird N., Dietz W. H., Rimm E., Colditz G. A., Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine 2001 161 13 1581 1586 2-s2.0-0034917709
2. Must A., Spadano J., Coakley E. H., Field A. E., Colditz G., Dietz W. H., The disease burden associated with overweight and obesity. Journal of the American Medical Association 1999 282 16 1523 1529 2-s2.0-0032742418 10.1001/jama.282.16.1523
3. Matsuzawa Y., Nakamura T., Takahashi M., Ryo M., Inoue S., Ikeda Y., Ohno M., Sakata T., Fukagawa K., Saitoh Y., Sato Y., Shirai K., Miyazaki S., Tokunaga K., Yamanouchi K., Takahashi M., Shibasaki T., Nagai M., New criteria for 'obesity disease' in Japan. Circulation Journal 2002 66 11 987 992 2-s2.0-0036856963 10.1253/circj.66.987
4. Matsushita Y., Takahashi Y., Mizoue T., Inoue M., Noda M., Tsugane S., Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study. International Journal of Obesity 2008 32 12 1861 1867 2-s2.0-57749179949 10.1038/ijo.2008.188
5. Bailey E. F., A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat, by Bariohay et al. American Journal of Physiology 2008 295 4 R1048 R1049 2-s2.0-57349188411 10.1152/ajpregu.90701.2008
6. Rehfeld J. F., The new biology of gastrointestinal hormones. Physiological Reviews 1998 78 4 1087 1108 2-s2.0-0031722813
7. Phillips R. J., Powley T. L., Gastric volume rather than nutrient content inhibits food intake. American Journal of Physiology 1996 271 3 R766 R779 2-s2.0-0029797077
8. Martin C. K., Bellanger D. E., Rau K. K., Coulon S., Greenway F. L., Safety of the Ullorex oral intragastric balloon for the treatment of obesity. Journal of Diabetes Science and Technology 2007 1 40 574 581
9. Rigaud D., Trostler N., Rozen R., Vallot T., Apfelbaum T., Gastric distension, hunger and energy intake after balloon implantation in severe obesity. International Journal of Obesity 1995 19 7 489 495
10. Schwartz G. J., The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 2000 16 10 866 873 2-s2.0-0033780625 10.1016/S0899-9007(00)00464-0
11. Schwartz G. J., Salorio C. F., Skoglund C., Moran T. H., Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. American Journal of Physiology 1999 276 6 R1623 R1629 2-s2.0-0033067578
12. Spiller R. C., Trotman I. F., Higgins B. E., The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984 25 4 365 374 2-s2.0-0021278421
13. Wen J., Phillips S. F., Sarr M. G., Kost L. J., Holst J. J., PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. American Journal of Physiology 1995 269 6 G945 G952 2-s2.0-0029558262
14. Yanovski S. Z., Yanovski J. A., Obesity. New England Journal of Medicine 2002 346 8 591 602 2-s2.0-0037148922 10.1056/NEJMra012586
15. Brolin R. E., Bariatric surgery and long-term control of morbid obesity. Journal of the American Medical Association 2002 288 22 2793 2796 2-s2.0-0037065354 10.1001/jama.288.22.2793
16. Cummings D. E., Overduin J., Foster-Schubert K. E., Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2608 2615 2-s2.0-2942689978 10.1210/jc.2004-0433
17. Tadross J. A., Le Roux C. W., The mechanisms of weight loss after bariatric surgery. International Journal of Obesity 2009 33 1 S28 S32 2-s2.0-64949170914 10.1038/ijo.2009.14
18. Favretti F., Ashton D., Busetto L., Segato G., De Luca M., The gastric band: first-choice procedure for obesity surgery. World Journal of Surgery 2009 33 10 2039 2048 2-s2.0-70349318019 10.1007/s00268-009-0091-6
19. Cummings D. E., Weigle D. S., Scott Frayo R., Breen P. A., Ma M. K., Patchen Dellinger E., Purnell J. Q., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine 2002 346 21 1623 1630 2-s2.0-0037162116 10.1056/NEJMoa012908
20. Korner J., Inabnet W., Febres G., Conwell I. M., McMahon D. J., Salas R., Taveras C., Schrope B., Bessler M., Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. International Journal of Obesity 2009 33 7 786 795 2-s2.0-67650417904 10.1038/ijo.2009.79
21. Le Roux C. W., Welbourn R., Werling M., Osborne A., Kokkinos A., Laurenius A., Lönroth H., Fändriks L., Ghatei M. A., Bloom S. R., Olbers T., Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 2007 246 5 780 785 2-s2.0-35649021752 10.1097/SLA.0b013e3180caa3e3
22. Bueter M., Löwenstein C., Olbers T., Wang M., Cluny N. L., Bloom S. R., Sharkey K. A., Lutz T. A., le Roux C. W., Gastric bypass increases energy expenditure in rats. Gastroenterology 2010 138 5 1845 1853.e1 2-s2.0-77951667606 10.1053/j.gastro.2009.11.012
23. Laville M., Disse E., Bariatric surgery for diabetes treatment: why should we go rapidly to surgery. Diabetes and Metabolism 2009 35 6 562 563 2-s2.0-75449092873 10.1016/S1262-3636(09)73466-4
24. Musso G., giovannimusso@yahoo.it Gambino R., Cassader M., Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 2010 33 10 2277 2284 10.2337/dc10-0556
25. Bäckhed F., Ding H., Wang T., Hooper L. V., Gou Y. K., Nagy A., Semenkovich C. F., Gordon J. I., The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of America 2004 101 44 15718 15723 2-s2.0-8144226856 10.1073/pnas.0407076101
26. Bäckhed F., Manchester J. K., Semenkovich C. F., Gordon J. I., Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America 2007 104 3 979 984 2-s2.0-33846542071 10.1073/pnas.0605374104
27. Cani P. D., Lecourt E., Dewulf E. M., Sohet F. M., Pachikian B. D., Naslain D., De Backer F., Neyrinck A. M., Delzenne N. M., Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. American Journal of Clinical Nutrition 2009 90 5 1236 1243 2-s2.0-70350662669 10.3945/ajcn.2009.28095
28. Tatemoto K., Mutt V., Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980 285 5764 417 418 2-s2.0-0019310264
29. Lin S., Boey D., Herzog H., NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004 38 4 189 200 2-s2.0-4444256688 10.1016/j.npep.2004.05.005
30. Eberlein G. A., Eysselein V. E., Schaeffer M., Layer P., Grandt D., Goebell H., Niebel W., Davis M., Lee T. D., Shively J. E., Reeve J. R., A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 1989 10 4 797 803 2-s2.0-0024420577
31. Adrian T. E., Ferri G. L., Bacarese-Hamilton A. J., Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985 89 5 1070 1077 2-s2.0-0022398837
32. Batterham R. L., Cowley M. A., Small C. J., Herzog H., Cohen M. A., Dakin C. L., Wren A. M., Brynes A. E., Low M. J., Ghatei M. A., Cone R. D., Bloom S. R., Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002 418 6898 650 654 2-s2.0-0037043704 10.1038/nature00887
33. Batterham R. L., Cohen M. A., Ellis S. M., Le Roux C. W., Withers D. J., Frost G. S., Ghatei M. A., Bloom S. R., Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine 2003 349 10 941 948 2-s2.0-0041859261 10.1056/NEJMoa030204
34. Adrian T. E., Savage A. P., Bacarese-Hamilton A. J., Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986 90 2 379 384 2-s2.0-0022651971
35. Wahab P. J., Hopman W. P. M., Jansen J. B. M. J., Basal and fat-stimulated plasma peptide YY levels in celiac disease. Digestive Diseases and Sciences 2001 46 11 2504 2509 2-s2.0-0034766970 10.1023/A:1012344424300
36. 3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. American Journal of Physiology 2007 292 4 E1062 E1068 10.1152/ajpendo.00450.2006
37. Boey D., Lin S., Enriquez R. F., Lee N. J., Slack K., Couzens M., Baldock P. A., Herzog H., Sainsbury A., PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008 42 1 19 30 2-s2.0-38549164620 10.1016/j.npep.2007.11.003
38. Talsania T., Anini Y., Siu S., Drucker D. J., Brubaker P. L., Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005 146 9 3748 3756 2-s2.0-23844554610 10.1210/en.2005-0473
39. Ashby D., Bloom S. R., Recent progress in PYY research-an update report for 8th NPY meeting. Peptides 2007 28 2 198 202 2-s2.0-33846585956 10.1016/j.peptides.2006.10.019
40. Bartolomé M. A., Borque M., Martinez-Sarmiento J., Aparicio E., Hernández C., Cabrerizo L., Fernández-Represa J. A., Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obesity Surgery 2002 12 3 324 327 2-s2.0-0035985531 10.1381/096089202321088084
41. Misra M., Miller K. K., Tsai P., Gallagher K., Lin A., Lee N., Herzog D. B., Klibanski A., Elevated peptide YY levels in adolescent girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2006 91 3 1027 1033 2-s2.0-33644824823 10.1210/jc.2005-1878
42. Kim B. J., Carlson O. D., Jang H. J., Elahi D., Berry C., Egan J. M., Peptide YY is secreted after oral glucose administration in a gender-specific manner. Journal of Clinical Endocrinology and Metabolism 2005 90 12 6665 6671 2-s2.0-28744450411 10.1210/jc.2005-0409
43. Pfluger P. T., Kampe J., Castaneda T. R., Vahl T., D'Alessio D. A., Kruthaupt T., Benoit S. C., Cuntz U., Rochlitz H. J., Moehlig M., Pfeiffer A. F. H., Koebnick C., Weickert M. O., Otto B., Spranger J., Tschöp M. H., Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. Journal of Clinical Endocrinology and Metabolism 2007 92 2 583 588 2-s2.0-33846997549 10.1210/jc.2006-1425
44. Halatchev I. G., Cone R. D., Peripheral administration of PYY3-36 produces conditioned taste aversion in mice. Cell Metabolism 2005 1 3 159 168 2-s2.0-17844395786 10.1016/j.cmet.2005.02.003
45. Abbott C. R., Monteiro M., Small C. J., Sajedi A., Smith K. L., Parkinson J. R. C., Ghatei M. A., Bloom S. R., The inhibitory effects of peripheral administration of peptide YY 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Research 2005 1044 1 127 131 2-s2.0-18144381593 10.1016/j.brainres.2005.03.011
46. Koda S., Date Y., Murakami N., Shimbara T., Hanada T., Toshinai K., Niijima A., Furuya M., Inomata N., Osuye K., Nakazato M., The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 2005 146 5 2369 2375 2-s2.0-20244369116 10.1210/en.2004-1266
47. Morley J. E., Levine A. S., Grace M., Kneip J., Peptide YY (PYY), a potent orexigenic agent. Brain Research 1985 341 1 200 203 2-s2.0-0022392297 10.1016/0006-8993(85)91490-8
48. Stanley B. G., Daniel D. R., Chin A. S., Leibowitz S. F., Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 1985 6 6 1205 1211 2-s2.0-0022396692
49. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., Fukami T., Morin N., Macneil D. J., Van Der Ploeg L. H. T., Saga Y., Nishimura S., Ihara M., Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000 141 3 1011 1016 2-s2.0-12144286708 10.1210/en.141.3.1011
50. Batterham R. L., Ffytche D. H., Rosenthal J. M., Zelaya F. O., Barker G. J., Withers D. J., Williams S. C. R., PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007 450 7166 106 109 2-s2.0-35948998870 10.1038/nature06212
51. Asakawa A., Inui A., Yuzuriha H., Ueno N., Katsuura G., Fujimiya M., Fujino M. A., Niijima A., Meguid M. M., Kasuga M., Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003 124 5 1325 1336 2-s2.0-0037847510 10.1016/S0016-5085(03) 00216-6
52. Parker R. M. C., Herzog H., Regional distribution of Y-receptor subtype mRNAs in rat brain. European Journal of Neuroscience 1999 11 4 1431 1448 2-s2.0-0033040237 10.1046/j.1460-9568.1999.00553.x
53. Whitcomb D. C., Taylor I. L., Vigna S. R., Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. American Journal of Physiology 1990 259 4 G687 G691 2-s2.0-0025012383
54. Clark J. T., Kalra P. S., Crowley W. R., Kalra S. P., Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984 115 1 427 429 2-s2.0-0021248888
55. Jorde R., Burhol P. G., Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. International Journal of Obesity 1984 8 5 393 397 2-s2.0-0021690055
56. Wisen O., Bjorvell H., Cantor P., Johansson C., Theodorsson E., Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regulatory Peptides 1992 39 1 43 54 2-s2.0-0026529733 10.1016/0167-0115(92)90007-H
57. Glaser B., Zoghlin G., Pienta K., Vinik A. I., Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Hormone and Metabolic Research 1988 20 5 288 292 2-s2.0-0023898345
58. Lassmann V., Vague P., Vialettes B., Simon M. C., Low plasma levels of pancreatic polypeptide in obesity. Diabetes 1980 29 6 428 430 2-s2.0-0019270026
59. Uhe A. M., Szmukler G. I., Collier G. R., Hansky J., O'Dea K., Young G. P., Potential regulators of feeding behavior in anorexia nervosa. American Journal of Clinical Nutrition 1992 55 1 28 32 2-s2.0-0026569358
60. Zipf W. B., O'Dorisio T. M., Cataland S., Dixon K., Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. Journal of Clinical Endocrinology and Metabolism 1983 57 5 1074 1080 2-s2.0-0021048887
61. Ueno N., Inui A., Iwamoto M., Kaga T., Asakawa A., Okita M., Fujimiya M., Nakajima Y., Ohmoto Y., Ohnaka M., Nakaya Y., Miyazaki J. I., Kasuga M., Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1999 117 6 1427 1432 2-s2.0-0032732394
62. Batterham R. L., Le Roux C. W., Cohen M. A., Park A. J., Ellis S. M., Patterson M., Frost G. S., Ghatei M. A., Bloom S. R., Pancreatic polypeptide reduces appetite and food intake in humans. Journal of Clinical Endocrinology and Metabolism 2003 88 8 3989 3992 2-s2.0-0041882174 10.1210/jc.2003-030630
63. Berntson G. G., Zipf W. B., O'Dorisio T. M., Hoffman J. A., Chance R. E., Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993 14 3 497 503 2-s2.0-0027190603 10.1016/0196-9781(93)90138-7
64. Holst J. J., On the physiology of GIP and GLP-1. Hormone and Metabolic Research 2004 36 11-12 747 754 2-s2.0-12244268666 10.1055/s-2004-826158
65. Tang-Christensen M., Vrang N., Larsen P. J., Glucagon-like peptide containing pathways in the regulation of feeding behaviour. International Journal of Obesity 2001 25 supplement 5 S42 S47 10.1038/sj/ijo/0801912
66. Tucker J. D., Dhanvantari S., Brubaker P. L., Proglucagon processing in islet and intestinal cell lines. Regulatory Peptides 1996 62 1 29 35 2-s2.0-0342748342 10.1016/0167-0115(95)00167-0
67. Deacon C. F., Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research 2004 36 11-12 761 765 2-s2.0-12244281855 10.1055/s-2004- 826160
68. Mentlein R., Gallwitz B., Schmidt W. E., Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993 214 3 829 835 2-s2.0-0027215348
69. Vilsboll T., tivi@gentoftehosp.kbhamt.dk Agerso H., Krarup T., Holst J. J., Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 1 220 224 10.1210/jc.2002-021053
70. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J. J., Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994 43 4 535 539 2-s2.0-0028281773
71. Holst J. J., The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 4 1409 1439 2-s2.0-35748957503 10.1152/physrev.00034.2006
72. Yamato E., Ikegami H., Takekawa K., Fujisawa T., Nakagawa Y., Hamada Y., Ueda H., Ogihara T., Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Hormone and Metabolic Research 1997 29 2 56 59 2-s2.0-0030996638
73. Vahl T. P., Drazen D. L., Seeley R. J., D'Alessio D. A., Woods S. C., Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 2010 151 2 569 575 2-s2.0-74949121349 10.1210/en.2009-1002
74. Cummings D. E., Overduin J., Gastrointestinal regulation of food intake. Journal of Clinical Investigation 2007 117 1 13 23 2-s2.0-33846032275 10.1172/JCI30227
75. Verdich C., Flint A., Gutzwiller J. P., Näslund E., Beglinger C., Hellström P. M., Long S. J., Morgan L. M., Holst J. J., Astrup A., A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on Ad Libitum energy intake in humans. Journal of Clinical Endocrinology and Metabolism 2001 86 9 4382 4389 2-s2.0-17944365214 10.1210/jc.86.9.4382
76. Zander M., Madsbad S., Madsen J. L., Holst J. J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β -cell function in type 2 diabetes: a parallel-group study. Lancet 2002 359 9309 824 830 2-s2.0-0037045845 10.1016/S0140-6736(02)07952-7
77. Eng J., Kleinman W. A., Singh L., Singh G., Raufman J. P., Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry 1992 267 11 7402 7405 2-s2.0-0026648961
78. DeFronzo R. A., Ratner R. E., Han J., Kim D. D., Fineman M. S., Baron A. D., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2. Diabetes Care 2005 28 5 1092 1100 2-s2.0-18144401971 10.2337/diacare.28.5.1092
79. Drucker D. J., Buse J. B., Taylor K., Kendall D. M., Trautmann M., Zhuang D., Porter L., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet 2008 372 9645 1240 1250 2-s2.0-53249142132 10.1016/S0140-6736(08)61206-4
80. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009 374 9683 39 47 2-s2.0-67649666737 10.1016/S0140-6736(09)60659-0
81. Egan J. M., Bulotta A., Hui H., Perfetti R., GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes/Metabolism Research and Reviews 2003 19 2 115 123 2-s2.0-0037357951 10.1002/dmrr.357
82. Harkavyi A., Whitton P. S., Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. British Journal of Pharmacology 2010 159 3 495 501 2-s2.0-76449115696 10.1111/j.1476-5381.2009.00486.x
83. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A. E., Biggs C. S., Whitton P. S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation 2008 5, article no. 19 2-s2.0-45549108268 10.1186/1742-2094-5- 19
84. Kim S., Moon M., Park S., Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. Journal of Endocrinology 2009 202 3 431 439 2-s2.0-70349334516 10.1677/JOE-09-0132
85. Li Y., Perry T., Kindy M. S., Harvey B. K., Tweedie D., Holloway H. W., Powers K., Shen H., Egan J. M., Sambamurti K., Brossi A., Lahiri D. K., Mattson M. P., Hoffer B. J., Wang Y., Greig N. H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 2009 106 4 1285 1290 2-s2.0-59049087723 10.1073/pnas.0806720106
86. Perry T., Lahiri D. K., Sambamurti K., Chen D., Mattson M. P., Egan J. M., Greig N. H., Glucagon-like peptide-1 decreases endogenous amyloid- β peptide (A β) levels and protects hippocampal neurons from death induced by A β and iron. Journal of Neuroscience Research 2003 72 5 603 612 2-s2.0-0038248960 10.1002/jnr.10611
87. Perry T. A., Greig N. H., A new Alzheimer's disease interventive strategy: GLP-1. Current Drug Targets 2004 5 6 565 571 2-s2.0-3442896818 10.2174/1389450043345245
88. Perry T., Holloway H. W., Weerasuriya A., Mouton P. R., Duffy K., Mattison J. A., Greig N. H., Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Experimental Neurology 2007 203 2 293 301 2-s2.0-33846501672 10.1016/j.expneurol.2006.09.028
89. Drucker D. J., Glucagon-like peptide 2. Trends in Endocrinology and Metabolism 1999 10 4 153 156 2-s2.0-0033020969 10.1016/S1043-2760(98)00136-2
90. Schmidt P. T., Peter.Thelin.Schmidt@medks.ki.se Näslund E., Grybäck P., Jacobsson H., Hartmann B., Holst J. J., Hellström P. M., Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regulatory Peptides 2003 116 1-3 21 25 10.1016/S0167-0115(03)00175-7
91. Drucker D. J., Ehrlich P., Asa S. L., Brubaker P. L., Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proceedings of the National Academy of Sciences of the United States of America 1996 93 15 7911 7916 2-s2.0-0029795016 10.1073/pnas.93.15.7911
92. Wallis K., Walters J. R. F., Forbes A., Review article: glucagon-like peptide 2-current applications and future directions. Alimentary Pharmacology and Therapeutics 2007 25 4 365 372 2-s2.0-33846581916 10.1111/j.1365-2036.2006. 03193.x
93. Buchman A. L., Katz S., Fang J. C., Bernstein C. N., Abou-Assi S. G., Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflammatory Bowel Diseases 2010 16 6 962 973 2-s2.0-77952679996 10.1002/ibd.21117
94. Nagell C. F., Wettergren A., Pedersen J. F., Mortensen D., Holst J. J., Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scandinavian Journal of Gastroenterology 2004 39 4 353 358 2-s2.0-1942485485 10.1080/00365520410004424
95. Ghatei M. A., Uttenthal L. O., Christofides N. D., Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. Journal of Clinical Endocrinology and Metabolism 1983 57 3 488 495
96. Cohen M. A., Ellis S. M., Le Roux C. W., Batterham R. L., Park A., Patterson M., Frost G. S., Ghatei M. A., Bloom S. R., Oxyntomodulin suppresses appetite and reduces food intake in humans. Journal of Clinical Endocrinology and Metabolism 2003 88 10 4696 4701 2-s2.0-0242288734 10.1210/jc.2003-030421
97. Dakin C. L., Gunn I., Small C. J., Edwards C. M. B., Hay D. L., Smith D. M., Ghatei M. A., Bloom S. R., Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001 142 10 4244 4250 2-s2.0-0034807498 10.1210/en.142.10.4244
98. Wynne K., Park A. J., Small C. J., Meeran K., Ghatei M. A., Frost G. S., Bloom S. R., Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International Journal of Obesity 2006 30 12 1729 1736 2-s2.0-33749339257 10.1038/sj.ijo.0803344
99. Dakin C. L., Small C. J., Batterham R. L., Neary N. M., Cohen M. A., Patterson M., Ghatei M. A., Bloom S. R., Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004 145 6 2687 2695 2-s2.0-2542460293 10.1210/en.2003-1338
100. Baggio L. L., Huang Q., Brown T. J., Drucker D. J., Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004 127 2 546 558 2-s2.0-4143116741 10.1053/j.gastro.2004.04.063
101. Sowden G. L., Drucker D. J., Weinshenker D., Swoap S. J., sswoap@williams.edu Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. American Journal of Physiology 2007 292 2 R962 R970 10.1152/ajpregu.00405.2006
102. Ban K., Kim K. H., Cho C. K., Sauvé M., Diamandis E. P., Backx P. H., Drucker D. J., Husain M., Glucagon-Like Peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010 151 4 1520 1531 2-s2.0-77950267745 10.1210/en.2009-1197
103. Druce M. R., Minnion J. S., Field B. C. T., Patel S. R., Shillito J. C., Tilby M., Beale K. E. L., Murphy K. G., Ghatei M. A., Bloom S. R., Investigation of structure-activity relationships of oxyntomodulin (Oxm) using oxm analogs. Endocrinology 2009 150 4 1712 1721 2-s2.0-63849300305 10.1210/en.2008-0828
104. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K., Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 6762 656 660 2-s2.0-0033540056 10.1038/45230
105. Cummings D. E., Purnell J. Q., Frayo R. S., Schmidova K., Wisse B. E., Weigle D. S., A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001 50 8 1714 1719 2-s2.0-0035433977
106. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S., A role for ghrelin in the central regulation of feeding. Nature 2001 409 6817 194 198 2-s2.0-0035843183 10.1038/35051587
107. Tschop M., Smiley D. L., Heiman M. L., Ghrelin induces adiposity in rodents. Nature 2000 407 6806 908 913 2-s2.0-0034687376 10.1038/35038090
108. Otto B., Cuntz U., Fruehauf E., Wawarta R., Folwaczny C., Riepl R. L., Heiman M. L., Lehnert P., Fichter M., Tschöp M., Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. European Journal of Endocrinology 2001 145 5 669 673 2-s2.0-0035512816
109. Le Roux C. W., Patterson M., Vincent R. P., Hunt C., Ghatei M. A., Bloom S. R., s.bloom@imperial.ac.uk Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. Journal of Clinical Endocrinology and Metabolism 2005 90 2 1068 1071 10.1210/jc.2004-1216
110. Nagaya N., Uematsu M., Kojima M., Date Y., Nakazato M., Okumura H., Hosoda H., Shimizu W., Yamagishi M., Oya H., Koh H., Yutani C., Kangawa K., Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001 104 17 2034 2038 2-s2.0-0035940390
111. Cummings D. E., Clement K., Purnell J. Q., Vaisse C., Foster K. E., Frayo R. S., Schwartz M. W., Basdevant A., Weigle D. S., Elevated plasma ghrelin levels in Prader-Willi syndrome. Nature Medicine 2002 8 7 643 644 2-s2.0-0036061558 10.1038/nm0702-643
112. Taheri S., Lin L., Austin D., Young T., Mignot E., Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Medicine 2004 1, article e62 2-s2.0-15744378271 10.1371/journal. pmed.0010062
113. Wang L., Saint-Pierre D. H., Taché Y., Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neuroscience Letters 2002 325 1 47 51 2-s2.0-0037204861 10.1016/S0304-3940(02)00241-0
114. Chen H. Y., Trumbauer M. E., Chen A. S., Weingarth D. T., Adams J. R., Frazier E. G., Shen Z., Marsh D. J., Feighner S. D., Guan X. M., Ye Z., Nargund R. P., Smith R. G., Van Der Ploeg L. H. T., Howard A. D., Macneil D. J., Qian S., Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004 145 6 2607 2612 2-s2.0-2542475178 10.1210/en.2003-1596
115. Lawrence C. B., Snape A. C., Baudoin F. M. H., Luckman S. M., Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002 143 1 155 162 2-s2.0-0036144322 10.1210/en.143.1.155
116. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., Nakazato M., The role of the gastric afferent vagal nerve in Ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002 123 4 1120 1128 2-s2.0-0036787457 10.1053/gast.2002.35954
117. Malik S., McGlone F., Bedrossian D., Dagher A., Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metabolism 2008 7 5 400 409 2-s2.0-42649116436 10.1016/j.cmet.2008.03.007
118. Gibbs J., Young R. C., Smith G. P., Cholecystokinin decreases food intake in rats. Journal of Comparative and Physiological Psychology 1973 84 3 488 495
119. Liddle R. A., Goldfine I. D., Rosen M. S., Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. Journal of Clinical Investigation 1985 75 4 1144 1152
120. Kissileff H. R., Pi-Sunyer F. X., Thornton J., Smith G. P., C-terminal octapeptide of cholecystokinin decreases food intake in man. American Journal of Clinical Nutrition 1981 34 2 154 160 2-s2.0-0019381381
121. Moran T. H., Baldessarini A. R., Salorio C. F., Lowery T., Schwartz G. J., Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. American Journal of Physiology 1997 272 4 R1245 R1251 2-s2.0-0030985882
122. Moran T. H., Katz L. F., Plata-Salaman C. R., Schwartz G. J., Disordered food intake and obesity in rats lacking cholecystokinin A receptors. American Journal of Physiology 1998 274 3 R618 R625 2-s2.0-0031944277
123. Wank S. A., Cholecystokinin receptors. American Journal of Physiology 1995 269 5 G628 G646 2-s2.0-0028845124
124. West D. B., Fey D., Woods S. C., Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. The American journal of physiology 1984 246 5 R776 R787 2-s2.0-0021433344
125. Crawley J. N., Beinfeld M. C., Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983 302 5910 703 706 2-s2.0-0020522487
126. Polonsky K. S., Given B. D., Van Cauter E., Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. Journal of Clinical Investigation 1988 81 2 442 448 2-s2.0-0023829632
127. Air E. L., aire@ucmail.uc.edu Benoit S. C., Blake Smith K. A., Clegg D. J., Woods S. C., Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacology Biochemistry and Behavior 2002 72 1-2 423 429 10.1016/S0091-3057(01)00780-8
128. Porte D. Jr., Woods S. C., Regulation of food intake and body weight by insulin. Diabetologia 1981 20 274 280 2-s2.0-0019498710
129. Considine R. V., Sinha M. K., Heiman M. L., Kriauciunas A., Stephens T. W., Nyce M. R., Ohannesian J. P., Marco C. C., Mckee L. J., Bauer T. L., Caro J. F., Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 1996 334 5 292 295 2-s2.0-13344295079 10.1056/NEJM199602013340503
130. Saad M. F., saad@hsc.usc.edu Riad-Gabriel M. G., Khan A., Sharma A., Michael R., Jinagouda S. D., Boyadjian R., Steil G. M., Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. Journal of Clinical Endocrinology and Metabolism 1998 83 2 453 459 10.1210/jc.83.2.453
131. Farooqi I. S., Jebb S. A., Langmack G., Lawrence E., Cheetham C. H., Prentice A. M., Hughes I. A., McCamish M. A., O'Rahilly S., Effects of recombinant leptin therapy in a child with congenital leptin deficiency. New
132. Zelissen P. M. J., Stenlof K., Lean M. E. J., Fogteloo J., Keulen E. T. P., Wilding J., Finer N., Rössner S., Lawrence E., Fletcher C., McCamish M., De Bruin T. W. A., Koppeschaar H. P. F., Sjöström L., Williams G., Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2005 7 6 755 761 2-s2.0-27744596187 10.1111/j.1463-1326. 2005.00468.x